SOPHiA GENETICS

What SOPHiA GENETICS does

SOPHiA GENETICS SA, founded in 2011 by Dr. Jurgi Camblong and dual-headquartered in Rolle, Switzerland and Boston, Massachusetts, operates a cloud-native, AI-driven SaaS platform called SOPHiA DDM™ that enables hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data while retaining control of patient samples and information. The platform combines proprietary algorithms (PEPPER, MUSKAT, CARDAMOM, GIInger, MUSTARD, MOKA, ABCD, STAR ANISE) with CUMIN® molecular barcoding technology and is tech-agnostic across major sequencing platforms (Illumina, Thermo Fisher, MGI, Element Biosciences, Complete Genomics). Application modules span solid tumors, hereditary cancers, blood cancers, liquid biopsy, rare disorders, and inherited disorders; add-on modules include Alamut™ Visual Plus variant interpretation and the newly launched SOPHiA DDM™ Digital Twins, which creates AI-driven virtual patient simulations for personalized oncology decision-making.

The company monetizes through a hybrid model: recurring platform subscriptions and per-analysis usage fees for the SOPHiA DDM™ cloud, plus higher-margin BioPharma services that include co-development of companion diagnostics (notably via the Myriad Genetics hybrid CDx partnership), clinical trial assay design, real-world data analytics, and biomarker discovery. Pricing is quote-based, with average selling price per patient reportedly rising from $50 in 2015 to $170 currently, and customer base of 537 core genomics customers across 990+ healthcare institutions in 75+ countries. The company also distributes white-labeled MSK-IMPACT® and MSK-ACCESS® assays through its MSK partnership and has expanded U.S. footprint via two large integrated health systems with up to 60,000 patients/year in hereditary cancer and rare disease applications.

SOPHiA GENETICS is publicly traded on Nasdaq (ticker SOPH), with FY2025 revenue of $77.3M (19% YoY), Q1 2026 revenue of $21.7M (22% YoY), 2026 guidance of $92-94M, 75% adjusted gross margin, and a 2026 adjusted EBITDA breakeven target. The company has 251-500 employees across 28 countries (30% with PhDs), holds multiple CE-IVD certifications (IVDR-compliant in EEA, UK, Switzerland, Israel), and is certified to ISO 27001/27017/27018, ISO 13485, SOC 2 Type 2, HIPAA, and GDPR. Recent capital actions include a $57.5M oversubscribed public offering in June 2026, a $50M debt facility from Perceptive Advisors (May 2024, expanded by $25M in early 2026), and a leadership transition effective July 1, 2026 with Ross Muken succeeding Dr. Camblong as CEO.

Name

SOPHiA GENETICS

Legal name

SOPHiA GENETICS SA

Website

https://sophiagenetics.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SOPHiA GENETICS operates SOPHiA DDM™, a cloud-native AI SaaS platform that enables hospitals, clinical labs, and biopharma to analyze and interpret genomic, radiomic, and multimodal healthcare data, serving 990+ institutions across 75+ countries with a hybrid recurring subscription and usage-based model.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

Keywords

• AI genomics platform
• Clinical decision support
• Companion diagnostics services
• Radiomics analysis software
• Variant interpretation software

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Platform Subscription / Recurring SaaS: Recurring subscription and per-test fees for use of the SOPHiA DDM™ cloud platform, including 'Dry Lab', 'Bundle' and 'Integrated Access Mode' offerings that combine IVD/RUO NGS applications with the platform; pricing is quote-based and not publicly disclosed.
2. Usage-Based Analysis Volume: Revenue scales with the number of genomic analyses processed on the platform; company has reported 35,000 patient cases processed monthly and 391,000 analyses in 2025; average selling price per patient increased from $50 (2015) to $170 currently.
3. BioPharma Companion Diagnostic & Trial Services: Revenue from co-development and deployment of companion diagnostics (CDx), clinical trial assays, real-world data analytics, and biomarker discovery with pharma/biotech partners; includes hybrid centralized/decentralized model with partners like Myriad Genetics.
4. Alamut™ Visual Plus Licensing: Standalone variant annotation/visualization software offered as an add-on module with a 'Request a Free Trial' CTA; represents licensing of proprietary software IP.
5. Professional Services & MaxCare Program: Tailored enablement, LIMS integration, application automation, training, and ongoing support services bundled with platform adoption under the SOPHiA DDM™ MaxCare Program.

Pricing tiers

Go-to-market motion5 records

Distribution channels5 records

Marketing channels9 records

Core offering

SOPHiA GENETICS builds and operates the SOPHiA DDM™ cloud-native AI platform that ingests raw NGS, radiomic and multimodal data and produces standardized, clinically validated variant interpretations and reports for hospitals, clinical laboratories and biopharma customers across 75+ countries. The platform is delivered as enterprise SaaS (Dry Lab, Bundle, Integrated Access Mode), with proprietary molecular barcoding (CUMIN®) and a suite of calling algorithms enabling CE-IVD genomic applications in oncology and rare disorders, and supports companion diagnostic co-development with pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• SOPHiA DDM™: AI-powered cloud-native SaaS platform for analyzing, standardizing, and interpreting complex healthcare data (genomic, radiomic, multimodal). Includes modules for Genomics, Radiomics, and Multimodal analysis.
• SOPHiA DDM™ Digital Twins
• MSK-ACCESS® powered with SOPHiA DDM™
• Alamut™ Visual Plus
• MSK-IMPACT® Flex powered with SOPHiA DDM™

Products and services

• SOPHiA DDM™ Platform
• SOPHiA DDM™ for Genomics

Quantifiable outcome

• 22% year-over-year revenue growth in Q1 2026 ($21.7M) and 19% growth in full-year 2025 ($77.3M); 20-22% projected for 2026.
• +9 more outcomes

Named customers18 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability12 records

Feature13 records

Partnerships

17 partnerships are on record, tiered flagship, core and minor.

• Memorial Sloan Kettering Cancer Center (MSK)flagshipStrategic or Co-development Partner · 4 June 2026Signed an MOU in June 2026 to form a joint venture establishing a precision medicine hub in New York City combining MSK's clinical data and 150,000+ sequenced tumor samples with SOPHiA DDM AI. Builds on previous licensing of MSK-IMPACT and MSK-ACCESS assays reaching 35 countries and a long-running co-development partnership on liquid biopsy (MSK-ACCESS) and comprehensive genomic profiling (MSK-IMPACT).
• SynnoviscoreStrategic or Co-development Partner · 13 May 2026UK pathology provider partnership to deliver MSK-ACCESS® liquid biopsy testing powered with SOPHiA DDM™ to lung and breast cancer patients across the U.K. as part of NHS England's 'blood test-first' program. Anticipates testing ~7,000 patients annually (≈one-third of all ctDNA tests in England), with patients receiving targeted therapy up to two weeks earlier.
• Mount Sinai Health SystemflagshipStrategic or Co-development Partner · 16 April 2026Mount Sinai adopted the SOPHiA DDM™ Platform at its NCI-designated Comprehensive Cancer Center in New York to enhance genomic testing for blood cancers and solid tumors, supporting 4,000+ oncology patients annually. Connects Mount Sinai's molecular pathology teams to a network of 800+ global institutions.
• Element BiosciencescoreTechnology or Integration · 5 March 2026Expanded partnership to integrate SOPHiA's AI-powered analytics with Element's AVITI and AVITI24 sequencing platforms. Joint go-to-market for clinical oncology research and targeted sequencing workflows.
• Mayo Clinic (expanded U.S. footprint)coreStrategic or Co-development Partner · 26 February 2026Part of the major U.S. expansion adding two large U.S. healthcare systems for genomic testing on up to 60,000 patients annually, leveraging the AI-native SOPHiA DDM platform.
• Two major U.S. integrated health systems (West Coast and Midwest)coreStrategic or Co-development Partner · 10 February 2026Signed two major integrated health systems (a leading nonprofit multi-region integrated healthcare system and a top 10 U.S. health system laboratory) to deploy the SOPHiA DDM Platform for hereditary cancers and rare diseases, with up to 60,000 patients tested annually.
• The University of Texas MD Anderson Cancer CenterflagshipStrategic or Co-development Partner · 7 January 2026Strategic collaboration to co-develop a next-generation sequencing oncology test on the SOPHiA DDM Platform and launch joint R&D programs focused on tumor evolution characterization, genomic testing reliability, and patient-specific clinical trial identification. Aims to translate multimodal data including RNA-sequencing into actionable insights for cancer diagnosis and treatment.
• Complete GenomicscoreTechnology or Integration · 5 December 2025Integration of MSK-IMPACT and MSK-ACCESS assays on the Complete Genomics DNBSEQ-T1+ sequencing platform, announced at AMP 2025. Provides laboratories with an end-to-end sample-to-report workflow for both liquid biopsy and solid tumor testing with concordant variant calls and lower background noise.
• A.D.A.M. Innovations Corporation (Japan)coreStrategic or Co-development Partner · 16 October 2025Strategic partnership in Japan to develop and commercialize liquid biopsy testing for personalized cancer care, initially launching the MSK-ACCESS® application. Samples analyzed locally in Japan to expedite turnaround times, reduce patient costs, and develop companion diagnostic tests.
• Myriad GeneticsflagshipStrategic or Co-development Partner · 23 September 2025First-of-its-kind hybrid CDx partnership combining Myriad's centralized CDx and regulatory expertise with SOPHiA's decentralized, data-driven platform. Co-developing an innovative liquid biopsy companion diagnostic test (initially MSK-ACCESS) for global clinical trials and healthcare.
• Jessa ZiekenhuisminorStrategic or Co-development Partner · 23 September 2025Announced precision oncology partnership from the European Congress of Pathology to deploy SOPHiA DDM solutions for the hospital.
• AstraZenecaflagshipStrategic or Co-development Partner · 5 August 2025Expanded collaboration to use SOPHiA DDM AI to improve detection of breast and prostate cancer and to accelerate liquid biopsy testing globally. AstraZeneca's AI strategy uses multimodal data from this partnership to tailor treatments to cancer patients.
• Mayo CliniccoreStrategic or Co-development Partner · 13 May 2024New partnership mentioned alongside SOPHiA's 2024 growth initiatives and Q1 2024 revenue results, supporting platform expansion and clinical use.
• ADC TherapeuticscoreStrategic or Co-development Partner · 28 April 2024Collaboration to identify genomic mutations correlating with clinical response to ADCT-402 in relapsed or refractory diffuse large B-cell lymphoma using SOPHiA's unique decentralized platform.
• Boundless BiocoreStrategic or Co-development Partner · 28 April 2024Partnering to develop the ECHO ecDNA detection algorithm into a clinical trial device on SOPHiA's cloud-based IVD NGS software platform.
• ARC RegulatorycoreImplementation/ SI/ Consulting Partner · 28 April 2024Collaboration to deliver an integrated solution for pharma companies in late-stage clinical development in Europe. Combines ARC Regulatory's IVDR-compliant clinical performance studies expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record, starting with co-development of a Clinical Trial Assay.
• Precision for MedicinecoreImplementation/ SI/ Consulting Partner · 28 April 2024Strategic alliance combining wet lab and translational expertise with SOPHiA's advanced analytics. Develops flexible clinical trial solutions that derive molecular signatures from complex data, advancing precision medicine through data-driven collaboration.

Scale indicators16 records

Recent moves8 records

Expansion highlights7 records

Emerging players

• Natera: Cell-free DNA testing company (Signatera MRD, Empower, Vistara) with a clinical biopharma services unit. Comparable in MRD/cfDNA testing, technology stack, and BioPharma customer segment, though more focused on solid-tumor recurrence than SOPHiA's broader CDx play.
• NeoGenomics: Clinical oncology and hematology lab with both wet-lab CGP services and an informatics platform (NeoGenomics Analytics). Comparable in oncology genomics lab services, hospital sales motion, and growing biopharma/CDx business.
• Personalis: Smaller oncology genomics company focused on CGP (NeXT Personal) and immuno-oncology biomarker analytics. Comparable in technology and customer type but at a smaller scale and narrower indication focus than SOPHiA.
• Veracyte: Genomic diagnostics company (Afirma, Decipher, Prosigna) with a growing AI/biomarker platform and BioPharma services arm. Comparable in the genomic test + biopharma CDx/data analytics model, though historically stronger in urologic/thyroid indications than oncology broadly.

Direct peers

• Tempus AI: Publicly traded AI-driven precision medicine company offering multimodal data analytics (genomics, imaging, clinical) for oncology providers and BioPharma. Closely comparable to SOPHiA GENETICS in business model, technology stack, customer base, and go-to-market motion.
• Caris Life Sciences: AI-driven molecular profiling company (MI Profile, Caris Assure) with both a sequencing services business and an AI/biopharma platform (Caris Discovery). Comparable because it serves the same oncology providers and biopharma customers with molecular profiling plus data analytics.
• Guardant Health: Liquid biopsy and oncology genomics company with its own proprietary cfDNA assays (Guardant360, Shield) and AI/ML pipelines. Directly comparable in oncology liquid biopsy, the specific area where SOPHiA is building MSK-ACCESS-powered CDx, and is also a litigation counterparty.

Others

• DNAnexus: Cloud-based genomics data management and analysis platform serving pharma, clinical labs, and research consortia. Comparable as a backend cloud genomics platform, though more of a horizontal infrastructure provider than a clinical-decision-support vendor.

Broad incumbents

• Illumina: Dominant NGS sequencing platform vendor that also offers DRAGEN bioinformatics software and IVD kits. Comparable because it competes for the same hospital sequencing + analysis budget and bundles its own software stack against SOPHiA DDM.
• Foundation Medicine (Roche): Roche subsidiary offering FoundationOne CDx comprehensive genomic profiling and a data analytics platform for oncology. Comparable in CGP, biopharma CDx services, and in competing for the same academic cancer center and pharma customers as SOPHiA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SOPHiAGENETICS
• YouTubeyoutube.com/channel/UCl5E7lH3GVZhfrgQoIKjvOQ
• Facebookfacebook.com/sophiagenetics
• LinkedInlinkedin.com/company/sophiagenetics
• Instagraminstagram.com/sophia_genetics

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOPHiA GENETICS